Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression

Human Pathology

Volumn 38, Issue 11, 2007, Pages 1628-1638

  Sood, Ashwani K ^a   Saxena, Rakhee ^a   Groth, Jeff ^a   Desouki, Mohamed M ^a   Cheewakriangkrai, Chalong ^a   Rodabaugh, Kerry J ^a   Kasyapa, Chitta S ^a   Geradts, Joseph ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Gleason score; PDEF; Prostate cancer; R1881; Tumor marker and target

Indexed keywords

PROTEIN PDEF; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE COURSE; GLEASON SCORE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MALE; METRIBOLONE; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; U937 CELLS;

EID: 35348902518     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.03.010     Document Type: Article

References (31)

1. Bray F., McCarron P., and Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6 (2004) 229-239
2. Chew H.K. Medical management of breast cancer: today and tomorrow. Cancer Biother Radiopharm 17 (2002) 137-149
3. Ward J.F., and Moul J.W. Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15 (2005) 181-186
4. Ward J.F., and Moul J.W. Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 15 (2005) 187-195
5. Ryan C.J., and Small E.J. Progress in detection and treatment of prostate cancer. Curr Opin Oncol 17 (2005) 257-260
6. O'Dwyer M.E., and Druker B.J. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets 1 (2001) 49-57
7. Jordan V.C., and Brodie A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 (2007) 7-25
8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
9. Scher H.I., Buchanan G., Gerald W., Butler L.M., and Tilley W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11 (2004) 459-476
10. Gold J.S., and Dematteo R.P. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244 (2006) 176-184
11. Oettgen P., Finger E., Sun Z., et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275 (2000) 1216-1225
12. Sharrocks A.D. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2 (2001) 827-837
13. Mimeault M. Structure-function studies of ETS transcription factors. Crit Rev Oncog 11 (2000) 227-253
14. Verger A., and Duterque-Coquillaud M. When Ets transcription factors meet their partners. Bioessays 24 (2002) 362-370
15. Gunawardane R.N., Sgroi D.C., Wrobel C.N., Koh E., Daley G.Q., and Brugge J.S. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65 (2005) 11572-11580
16. Mostofi F.K., Sesterhenn I., Davis C.J., and Sobin L.H. Histological typing of prostate tumours. (World Health Organisation, International histological classification of tumours). Ed 2 (2002), Springer, Berlin
17. Galang C.K., Muller W.J., Foos G., Oshima R.G., and Hauser C.A. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 279 (2004) 11281-11292
18. Ghadersohi A., and Sood A.K. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 7 (2001) 2731-2738
19. Nozawa M., Yomogida K., Kanno N., et al. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 60 (2000) 1348-1352
20. Feldman R.J., Sementchenko V.I., Gayed M., Fraig M.M., and Watson D.K. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63 (2003) 4626-4631
21. Ghadersohi A., Pan D., Fayazi Z., Hicks D.G., Winston J.S., and Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 102 (2007) 19-30
22. He J., Pan Y., Hu J., Albarracin C., Wu Y., and Le Dai J. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 6 (2007) 76-82
23. Veldhuis J.D., Keenan D.M., and Iranmanesh A. Mechanisms of ensemble failure of the male gonadal axis in aging. J Endocrinol Invest 28 (2005) 8-13
24. Haren M.T., Morley J.E., Chapman I.M., O'Loughlin P.D., and Wittert G.A. Defining 'relative' androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health. Climacteric 5 (2002) 15-25
25. Hijazi R.A., and Cunningham G.R. Andropause: is androgen replacement therapy indicated for the aging male. Annu Rev Med 56 (2005) 117-137
26. Santos G.C., Zielenska M., Prasad M., and Squire J.A. Chromosome 6p amplification and cancer progression. J Clin Pathol 60 (2007) 1-7
27. Libermann T.A., and Zerbini L.F. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 6 (2006) 17-33
28. Zhang Z., Li M., Rayburn E.R., Hill D.L., Zhang R., and Wang H. Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am J Pharmacogenomics 5 (2005) 327-338
29. Redell M.S., and Tweardy D.J. Targeting transcription factors for cancer therapy. Curr Pharm Des 11 (2005) 2873-2887
30. Rhodes A., Jasani B., Balaton A.J., Barnes D.M., and Miller K.D. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53 (2000) 688-696
31. Elledge R.M., and Osborne C.K. Oestrogen receptors and breast cancer. BMJ 314 (1997) 1843-1844